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Background:  There are no treatment guidelines for refractory Kawasaki disease (rKD). The purpose of this study was to assess practice 
variation and resource utilization for patients with rKD in a multicenter cohort.
methods:  All patients <18 years old with rKD (defined as receiving >1 dose of IVIG) between 2007-14 were identified from the Pediatric 
Health Information System (45 hospitals). Data collected: demographics, medications, complications, length of stay (LOS), and charges. 
Multivariable regression was used to determine factors associated with LOS.
results:  Of 14,306 episodes of KD (60% male), 21% (2,980, 63% male) had rKD. Compared to those receiving 1 dose of IVIG, rKD 
patients were slightly older (median age 33 vs. 32 mos), had greater LOS (5 vs. 3 days) and higher charges ($43,371 vs. $23,523) 
(p<0.001 for all). There was wide practice variation in the use of immunomodulators and anticoagulants in rKD. Immunomodulators 
included steroids 21%, infliximab 6%, cyclosporine 0.7%, abciximab 0.5%, methotrexate 0.3%, etanercept 0.2%, and rituximab 0.03%. 
Anticoagulants included enoxaparin 2%, warfarin 1.7%, tPA 2%, clopidogrel 2%, and dipyridamole 0.7%. Numerous factors were 
associated with LOS (Table).
Conclusion:  In rKD, the wide practice variation in the selection of immunomodulators and anticoagulants may reflect the absence of 
evidence and lack of consensus for optimal management. We identified predictors associated with longer LOS that may be used for 
counseling and resource allocation.
Factors affecting length of stay (LOS) in refractory KD (multivariable model)
Variables Categories N (%) Median LOS Adjusted Risk Ratio (95%CI) P-value
(IQR)
Census region Midwest 760 (26) 3 (2, 5) 0.93 (0.88, 0.98) 0.008
Northeast 412 (14) 3 (2, 5) 1.01 (0.97, 1.05) 0.690
South 1097 (37) 3 (2, 5) 0.98 (0.93, 1.03) 0.460
West 711 (24) 3 (2, 4) Reference .
Insurance type Medicaid 1102 (37) 3 (2, 5) 1.14 (0.96, 1.36) 0.140
Medicare 22 (1) 4 (3, 6) 0.95 (0.91, 1) 0.040
Other 528 (18) 3 (2, 5) 0.93 (0.9, 0.97) <.001
Private 1328 (45) 3 (2, 4) Reference .
Intensive care unit admission Yes 393 (13) 7 (4, 11) 1.12 (1.05, 1.19) <.001
No 2587 (87) 3 (2, 4) Reference .
Mechanical ventilation Yes 96 (3) 13 (8, 20) 1.41 (1.28, 1.56) <.001
No 2884 (97) 3 (2, 5) Reference .
Steroids Yes 627 (21) 9 (6, 13) 1.46 (1.4, 1.52) <.001
No 2353 (79) 5 (4, 6) Reference .
Other immunomodulators Yes 219 (7) 10 (7, 17) 1.35 (1.27, 1.44) <.001
No 2761 (93) 5 (4, 7) Reference .
Anticoagulants (beyond aspirin) Yes 261 (9) 11 (8, 19) 1.44 (1.35, 1.54) <.001
No 2719 (91) 5 (4, 7) Reference .
Seizures/neurologic sequelae Yes 212 (7) 7 (5, 12) 1.18 (1.11, 1.26) <.001
No 2768 (93) 5 (4, 8) Reference .
Heart failure medications Yes 772 (26) 8 (6, 12) 1.21 (1.15, 1.26) <.001
No 2208 (74) 5 (4, 7) Reference .
Shock/cardiac arrest Yes 277 (9) 9 (6, 13) 1.1 (1.03, 1.17) 0.006
No 2703 (91) 5 (4, 7) Reference .
Arrhythmia Yes 184 (6) 9 (6, 15) 1.13 (1.06, 1.21) <.001
No 2796 (94) 5 (4, 7) Reference .
Renal failure Yes 56 (2) 7 (4, 12) 1.18 (1.05, 1.33) 0.006
No 2924 (98) 5 (4, 8) Reference .
Concomitant viral infection Yes 322 (11) 7 (5, 10) 1.14 (1.08, 1.2) <.001
No 2658 (89) 5 (4, 8) Reference .
Congenital defects Yes 30 (1) 4 (3, 8) 1.31 (1.12, 1.52) <.001
No 2950 (99) 3 (2, 5) Reference .
